HONG KONG, Aug. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The clearance allows initiation of...
GROWING SALES TO US$8.3 BILLION, NET PROFIT INCREASED TO US$738 MILLION HONG KONG, Aug. 4, 2026 /PRNewswire/ -- Techtronic Industries Co. Ltd. ("TTI" or...